apc anti human cd34  (BioLegend)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Name:
    APC anti human CD34
    Description:
    APC anti human CD34 581 Isotype Mouse IgG1 κ Reactivity Human Cross Reactivity Cynomolgus Apps FC Size 25 tests
    Catalog Number:
    343509
    Price:
    110
    Category:
    Human Immunology
    Source:
    Mouse
    Applications:
    FC
    Conjugate:
    APC
    Size:
    25 tests
    Quantity:
    1
    Preparation:
    The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions The solution is free of unconjugated APC and unconjugated antibody
    Buy from Supplier


    Structured Review

    BioLegend apc anti human cd34
    APC anti human CD34
    APC anti human CD34 581 Isotype Mouse IgG1 κ Reactivity Human Cross Reactivity Cynomolgus Apps FC Size 25 tests
    https://www.bioz.com/result/apc anti human cd34/product/BioLegend
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    apc anti human cd34 - by Bioz Stars, 2021-05
    94/100 stars

    Images

    1) Product Images from "Effect of Muscle Cell Preservation on Viability and Differentiation of Hamstring Tendon Graft In Vitro"

    Article Title: Effect of Muscle Cell Preservation on Viability and Differentiation of Hamstring Tendon Graft In Vitro

    Journal: Cells

    doi: 10.3390/cells10040740

    ALP was highly expressed in MDCs compared with TDCs. ( a ) Tendon and muscle surface markers such as ALP, CD59, CD90, CD105, CD146, CD11b, CD34, CD45, CD74, and CD164 were analyzed by FACS. ( b ) Quantification of surface ALP expression (n = 6). ( c ) All TDCs and MDCs were cultured in growth medium for a day and cells were assessed with ALP staining (scale bar = 200 µm, ( d ) ALP activity (n = 4), or ( e ) qPCR for ALP mRNA expression (n = 5). *, p
    Figure Legend Snippet: ALP was highly expressed in MDCs compared with TDCs. ( a ) Tendon and muscle surface markers such as ALP, CD59, CD90, CD105, CD146, CD11b, CD34, CD45, CD74, and CD164 were analyzed by FACS. ( b ) Quantification of surface ALP expression (n = 6). ( c ) All TDCs and MDCs were cultured in growth medium for a day and cells were assessed with ALP staining (scale bar = 200 µm, ( d ) ALP activity (n = 4), or ( e ) qPCR for ALP mRNA expression (n = 5). *, p

    Techniques Used: FACS, Expressing, Cell Culture, Staining, Activity Assay, Real-time Polymerase Chain Reaction

    Related Articles

    other:

    Article Title: STAT3 supports experimental K-RasG12D–induced murine myeloproliferative neoplasms dependent on serine phosphorylation
    Article Snippet: Antibodies used: DX-5-allophycocyanin (APC)-Cy7, IL-7Rα-APC-Cy7 (A7R34), TER119-APC-Cy7, CD11b-APC-Cy7 (M1/70), B220-APC-Cy7 (RA3-6B2), CD4-APC-Cy7 (H129.19), CD8α-APC-Cy7 (53-6.7), c-Kit-fluorescein isothiocyanate (FITC) (2B8), Sca-1-phycoerythrin (PE)-Cy7 (D7), CD34-APC (RAM34), FCγR-Alexa 700 (2.4G2) (BioLegend); STAT3 (pY705)-Alexa 488 (BD Pharmingen); STAT3 (pS727), STAT3 (pY705) (Cell Signaling Technology); pSTAT5 (Zymed); phosphorylated extracellular signal-regulated kinase (pERK) (Santa Cruz Biotechnology).

    Flow Cytometry:

    Article Title: The TGF-β System As a Potential Pathogenic Player in Disease Modulation of Amyotrophic Lateral Sclerosis
    Article Snippet: Cells were then washed twice in phosphate-buffered saline (PBS, Sigma– Aldrich, St. Louis, MO, USA) containing 2% fetal bovine serum (FBS, PAA Laboratories, Pasching, Austria). .. For flow cytometric analysis cells were stained for 30 min at 4°C with combinations of the following murine monoclonal antibodies: anti-CD45-fluorescein-isothiocyanate (FITC, clone HI30; BD Pharmingen, Franklin Lakes, NJ, USA) and CD34-allophycocyanin (APC, clone 581, Biolegend, San Diego, CA, USA). .. After the labeling procedure, cells were washed twice with PBS2%FBS and subsequently analyzed using a Becton Dickinson FACSCalibur® flow cytometer.

    Article Title: Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma
    Article Snippet: Luciferase activity was determined by the ONE-Glo luciferase assay system (Promega). .. Flow Cytometry Allophycocyanin (APC)-labeled antibodies against human CD3, CD14, CD19, CD34, and CD138 were purchased from BioLegend. .. Labeled cells were quantified using the FACSCalibur flow cytometer (BD Biosciences).

    Article Title: Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer
    Article Snippet: Each cord was given an HM— numerical designation, and HSPCs were magnetically purified from the cord by CD34+ selection (Stemcell Technologies, Vancouver, BC; Cat#18086), suspended in expansion media supplemented with Flt3, SCF, IL-3, and IL-6 cytokines and human low-density lipoprotein (LDL; Stemcell Technologies; Cat#02698), and cultured at 37°C, 5% CO2 for 8–10 days. .. The initial HSPC population was calculated by flow cytometry, using human CD34 and CD45 (Biolegend, San Diego, CA; Cat#343608, 368510) antibodies. .. MSC-like cells were characterized by the presence of CD73 and CD166 antigens (Biolegend; Cat#344006, 343904).

    Staining:

    Article Title: The TGF-β System As a Potential Pathogenic Player in Disease Modulation of Amyotrophic Lateral Sclerosis
    Article Snippet: Cells were then washed twice in phosphate-buffered saline (PBS, Sigma– Aldrich, St. Louis, MO, USA) containing 2% fetal bovine serum (FBS, PAA Laboratories, Pasching, Austria). .. For flow cytometric analysis cells were stained for 30 min at 4°C with combinations of the following murine monoclonal antibodies: anti-CD45-fluorescein-isothiocyanate (FITC, clone HI30; BD Pharmingen, Franklin Lakes, NJ, USA) and CD34-allophycocyanin (APC, clone 581, Biolegend, San Diego, CA, USA). .. After the labeling procedure, cells were washed twice with PBS2%FBS and subsequently analyzed using a Becton Dickinson FACSCalibur® flow cytometer.

    Article Title: Biomarker Supervised G-CSF (Filgrastim) Response in ALS Patients
    Article Snippet: Peripheral blood CD34+ and CD34+ CD38− hematopoietic stem and progenitor cells (HSPC) were analyzed by flow cytometry as earlier described by our group ( ). .. In short, 1 ml donor blood was lysed in 9 ml NH4 Cl lysis buffer and cells were then stained for 30 min at 4°C with combinations of anti-CD45-FITC (clone HI30, BD Pharmingen, Franklin Lakes, NJ, USA), CD34-APC (clone 581, Biolegend, San Diego, CA, USA) and CD38-PE (clone HIT2, BioLegend) monoclonal antibodies. .. Analysis was performed on a Becton Dickinson CALIBUR flow cytometer (BD, East Rutherford, NJ, US).

    Lysis:

    Article Title: Biomarker Supervised G-CSF (Filgrastim) Response in ALS Patients
    Article Snippet: Peripheral blood CD34+ and CD34+ CD38− hematopoietic stem and progenitor cells (HSPC) were analyzed by flow cytometry as earlier described by our group ( ). .. In short, 1 ml donor blood was lysed in 9 ml NH4 Cl lysis buffer and cells were then stained for 30 min at 4°C with combinations of anti-CD45-FITC (clone HI30, BD Pharmingen, Franklin Lakes, NJ, USA), CD34-APC (clone 581, Biolegend, San Diego, CA, USA) and CD38-PE (clone HIT2, BioLegend) monoclonal antibodies. .. Analysis was performed on a Becton Dickinson CALIBUR flow cytometer (BD, East Rutherford, NJ, US).

    Incubation:

    Article Title: Melatonin Reverses the Loss of Stemness Induced by TNF-α in Human Bone Marrow Mesenchymal Stem Cells through Upregulation of YAP Expression
    Article Snippet: Flow Cytometry BMMSCs were analyzed by flow cytometry (DxFLEX, Beckman Coulter, USA). .. Cells at P3 were incubated in PE anti-human CD73 (Ecto-5′-nucleotidase) (BioLegend, USA), PE anti-human CD73 (Ecto-5′-nucleotidase) (BioLegend, USA), APC anti-human CD90 (Thy1) (BioLegend, USA), APC anti-human CD34 (BioLegend, USA), Alexa Fluor® 488 anti-human CD45 (BioLegend, USA), and Alexa Fluor® 488 anti-human CD105 (Abcam, USA) at concentrations specified by the manufacturer. ..

    Article Title: Studies in an Early Development Window Unveils a Severe HSC Defect in both Murine and Human Fanconi Anemia
    Article Snippet: This lineageneg fraction was incubated with SCA-1 (APC) and AA4.1 (PE) antibodies (Biolegend, BLE108112 and BLE136504) and SCA-1+ AA4.1+ cells (LSA) sorted on a FACSAria SORT cell sorter (BD Biosciences). .. Human FL cells were sorted after incubation with CD34 (APC), CD38 (FITC), CD45 (PE-Cy7) and CD117 (PE) antibodies (Biolegend, BLE343510, BLE303504, BLE304016 and BLE313204). ..

    Cytometry:

    Article Title: Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma
    Article Snippet: Luciferase activity was determined by the ONE-Glo luciferase assay system (Promega). .. Flow Cytometry Allophycocyanin (APC)-labeled antibodies against human CD3, CD14, CD19, CD34, and CD138 were purchased from BioLegend. .. Labeled cells were quantified using the FACSCalibur flow cytometer (BD Biosciences).

    Article Title: Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer
    Article Snippet: Each cord was given an HM— numerical designation, and HSPCs were magnetically purified from the cord by CD34+ selection (Stemcell Technologies, Vancouver, BC; Cat#18086), suspended in expansion media supplemented with Flt3, SCF, IL-3, and IL-6 cytokines and human low-density lipoprotein (LDL; Stemcell Technologies; Cat#02698), and cultured at 37°C, 5% CO2 for 8–10 days. .. The initial HSPC population was calculated by flow cytometry, using human CD34 and CD45 (Biolegend, San Diego, CA; Cat#343608, 368510) antibodies. .. MSC-like cells were characterized by the presence of CD73 and CD166 antigens (Biolegend; Cat#344006, 343904).

    Chloramphenicol Acetyltransferase Assay:

    Article Title: Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer
    Article Snippet: Each cord was given an HM— numerical designation, and HSPCs were magnetically purified from the cord by CD34+ selection (Stemcell Technologies, Vancouver, BC; Cat#18086), suspended in expansion media supplemented with Flt3, SCF, IL-3, and IL-6 cytokines and human low-density lipoprotein (LDL; Stemcell Technologies; Cat#02698), and cultured at 37°C, 5% CO2 for 8–10 days. .. The initial HSPC population was calculated by flow cytometry, using human CD34 and CD45 (Biolegend, San Diego, CA; Cat#343608, 368510) antibodies. .. MSC-like cells were characterized by the presence of CD73 and CD166 antigens (Biolegend; Cat#344006, 343904).

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    BioLegend anti human cd34 apc cyanine7
    Inhibition of αvβ3 and αvβ5 integrins impairs HE development without affecting EHT. A, qRT‐PCR analysis of RUNX1 , GATA2 and MYB expression in the day 6 VTN‐coated cells treated with or without Cilengitide at Days 2‐4 or Days 4‐6. Control was normalized to 1. n = 3. B and C, Flow cytometric analysis of the frequency and number (fold change) of CD43 + cells in the day 6 VTN‐coated cells treated with or without Cilengitide at Days 2‐4 or Days 4‐6. Control was normalized to 1. n = 3. D and E, Flow cytometric analysis of the frequency and number (fold change) of CD43 + cells in the day 6 VTN‐coated cells treated with or without SB‐273005 or ATN‐161 at Days 2‐4 or Days 4‐6. Control was normalized to 1. n = 3. F, Representative flow cytometric analysis of the frequency of day 4 <t>CD34</t> + CD144 + cells treated with or without Cilengitide at Days 2‐4. n = 3. G, qRT‐PCR analysis of RUNX1 and GATA2 expression in the day 4 cells treated with or without Cilengitide at Days 2‐4. Control was normalized to 1. n = 3. H, Scheme depicting the strategy used for evaluating the haematopoietic potential of day 4 CD34 + CD144 + CD43 − CD73 − CD184 − cells treated with or without Cilengitide at Days 2‐4. The day 4 CD34 + CD144 + CD43 − CD73 − CD184 − cells treated with or without Cilengitide at Days 2‐4 were sorted and then re‐seeded on VTN‐coated plates for an additional 4 days of EHT culture for HPC generation. I, The number of CD43 + cells generated from the day 4 CD34 + CD144 + CD43 − CD73 − CD184 − cells treated with or without Cilengitide at Days 2‐4 following an additional 4 days of EHT culture. n = 3. Experiments were performed on H1 unless otherwise indicated
    Anti Human Cd34 Apc Cyanine7, supplied by BioLegend, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti human cd34 apc cyanine7/product/BioLegend
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti human cd34 apc cyanine7 - by Bioz Stars, 2021-05
    94/100 stars
      Buy from Supplier

    94
    BioLegend cd34
    Myeloma Cells Are Sensitive to VV (A) Infectivity of leukemia/myeloma cell lines to VV. Cell lines derived from acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), malignant lymphoma, and multiple myeloma were infected with a firefly-luciferase-expressing VV (LC16m8Δ-B5R-FlucIRESgfp) at an MOI of 1. Luciferase activity was determined at 12 hr after infection. Data represent the means and SD of three independent experiments. (B) Cell viability after infection. Cells (1 × 10 4 /well) were seeded in 96-well plates and cultured for 72 hr in the absence or presence of different concentrations of the VV strain LC16m8Δ-B5R-FlucIRESgfp (MOIs = 0–8). The number of viable cells was determined using the Cell Counting Kit-8 (Dojindo). Data represent the mean and SD of three independent experiments. (C) Cells were infected with LC16m8Δ-B5Rgfp at an MOI of 0.1. Extracellular enveloped virus (EEV) and intracellular mature virus (IMV) were collected from supernatant and cell pellet at 72 hr after infection. Harvested virus was titrated by the infection to RK13 cells. Data represent the means and SD of three independent experiments. (D) Infectivity of myeloma patient bone marrow cells. Bone marrow mononuclear cells derived from a myeloma patient were infected with LC16m8Δ-B5Rgfp at an MOI of 1 and cultured for 48 hr. The frequency of virus-infected cells (GFP + ) was compared among <t>CD34</t> + cells (hematopoietic progenitors), CD138 + cells (myeloma), CD3 + cells (T lymphocytes), CD19 + cells (B lymphocytes), and CD14 + cells (monocytes). Histograms of non-infected cells (blue) are overlaid with infected cells (red).
    Cd34, supplied by BioLegend, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd34/product/BioLegend
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd34 - by Bioz Stars, 2021-05
    94/100 stars
      Buy from Supplier

    99
    BioLegend cd14
    The proportions of TNF-α–producing <t>CD14</t> + monocytes arelower than in the controls in FA and DBA. Bone marrow mononuclear cells werestimulated with 1 μg/ml of LPS for 4 h and stained for CD19 and CD14, andthen for intracellular
    Cd14, supplied by BioLegend, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd14/product/BioLegend
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd14 - by Bioz Stars, 2021-05
    99/100 stars
      Buy from Supplier

    N/A
    APC Fire 750 anti human CD134 OX40 Ber ACT35 ACT35 Isotype Mouse IgG1 κ Reactivity Human Cross Reactivity Chimpanzee Apps FC Size 25 tests
      Buy from Supplier

    Image Search Results


    Inhibition of αvβ3 and αvβ5 integrins impairs HE development without affecting EHT. A, qRT‐PCR analysis of RUNX1 , GATA2 and MYB expression in the day 6 VTN‐coated cells treated with or without Cilengitide at Days 2‐4 or Days 4‐6. Control was normalized to 1. n = 3. B and C, Flow cytometric analysis of the frequency and number (fold change) of CD43 + cells in the day 6 VTN‐coated cells treated with or without Cilengitide at Days 2‐4 or Days 4‐6. Control was normalized to 1. n = 3. D and E, Flow cytometric analysis of the frequency and number (fold change) of CD43 + cells in the day 6 VTN‐coated cells treated with or without SB‐273005 or ATN‐161 at Days 2‐4 or Days 4‐6. Control was normalized to 1. n = 3. F, Representative flow cytometric analysis of the frequency of day 4 CD34 + CD144 + cells treated with or without Cilengitide at Days 2‐4. n = 3. G, qRT‐PCR analysis of RUNX1 and GATA2 expression in the day 4 cells treated with or without Cilengitide at Days 2‐4. Control was normalized to 1. n = 3. H, Scheme depicting the strategy used for evaluating the haematopoietic potential of day 4 CD34 + CD144 + CD43 − CD73 − CD184 − cells treated with or without Cilengitide at Days 2‐4. The day 4 CD34 + CD144 + CD43 − CD73 − CD184 − cells treated with or without Cilengitide at Days 2‐4 were sorted and then re‐seeded on VTN‐coated plates for an additional 4 days of EHT culture for HPC generation. I, The number of CD43 + cells generated from the day 4 CD34 + CD144 + CD43 − CD73 − CD184 − cells treated with or without Cilengitide at Days 2‐4 following an additional 4 days of EHT culture. n = 3. Experiments were performed on H1 unless otherwise indicated

    Journal: Cell Proliferation

    Article Title: Vitronectin‐activated αvβ3 and αvβ5 integrin signalling specifies haematopoietic fate in human pluripotent stem cells, et al. Vitronectin‐activated αvβ3 and αvβ5 integrin signalling specifies haematopoietic fate in human pluripotent stem cells

    doi: 10.1111/cpr.13012

    Figure Lengend Snippet: Inhibition of αvβ3 and αvβ5 integrins impairs HE development without affecting EHT. A, qRT‐PCR analysis of RUNX1 , GATA2 and MYB expression in the day 6 VTN‐coated cells treated with or without Cilengitide at Days 2‐4 or Days 4‐6. Control was normalized to 1. n = 3. B and C, Flow cytometric analysis of the frequency and number (fold change) of CD43 + cells in the day 6 VTN‐coated cells treated with or without Cilengitide at Days 2‐4 or Days 4‐6. Control was normalized to 1. n = 3. D and E, Flow cytometric analysis of the frequency and number (fold change) of CD43 + cells in the day 6 VTN‐coated cells treated with or without SB‐273005 or ATN‐161 at Days 2‐4 or Days 4‐6. Control was normalized to 1. n = 3. F, Representative flow cytometric analysis of the frequency of day 4 CD34 + CD144 + cells treated with or without Cilengitide at Days 2‐4. n = 3. G, qRT‐PCR analysis of RUNX1 and GATA2 expression in the day 4 cells treated with or without Cilengitide at Days 2‐4. Control was normalized to 1. n = 3. H, Scheme depicting the strategy used for evaluating the haematopoietic potential of day 4 CD34 + CD144 + CD43 − CD73 − CD184 − cells treated with or without Cilengitide at Days 2‐4. The day 4 CD34 + CD144 + CD43 − CD73 − CD184 − cells treated with or without Cilengitide at Days 2‐4 were sorted and then re‐seeded on VTN‐coated plates for an additional 4 days of EHT culture for HPC generation. I, The number of CD43 + cells generated from the day 4 CD34 + CD144 + CD43 − CD73 − CD184 − cells treated with or without Cilengitide at Days 2‐4 following an additional 4 days of EHT culture. n = 3. Experiments were performed on H1 unless otherwise indicated

    Article Snippet: The dissociated cells were resuspended in FACS buffer and labelled with fluorochrome‐conjugated anti‐human CD34‐APC/Cyanine7 (clone 561, BioLegend), KDR‐PE (clone ES8‐20E6, Miltenyi Biotec), CD31‐FITC (clone AC128, Miltenyi Biotec), CD144‐APC (clone 16B1, eBioscience), CD43‐PerCP (clone TP1/36, Abcam), CD45‐APC (clone 2D1, BioLegend), CD144‐PE (clone BV9, BioLegend), CD43‐FITC (clone MEM‐59, BioLegend), CD73‐PE/Cyanine7 (clone AD2, BioLegend), CD184‐APC (clone 12G5, BioLegend), CD51/61‐FITC (clone 23C6, BioLegend), integrin β5‐PE (clone AST‐3T, BioLegend) and APLNR‐Alexa Fluor 647 (clone 72133R, RD system).

    Techniques: Inhibition, Quantitative RT-PCR, Expressing, Generated

    VTN promotes early haematopoietic differentiation of hPSCs, compared to MTG. A, Schematic showing the strategy for the generation of hPSC‐derived haematopoietic cells in VTN or MTG‐coated cultures. B and C, Flow cytometric analysis of the frequency and number of CD43 + and CD34 + CD43 ‐ cells on day 6. n = 3. D, The representative images showed that haematopoietic‐like cells with round shape and endothelium‐like cells undergoing EHT emerged in VTN‐coated culture on day 6. Scale bars, left 100 µm, right 50 µm. n = 3. E, qRT‐PCR analysis of RUNX1 , GATA2 and MYB expression in the day 6 cells coated with VTN or MTG. n = 3. F, CD43 + cell number on day 8 generated in VTN, MTG or GR‐MTG‐coated culture. MTG was set as a control and normalized to 1. n = 3. G and H, Flow cytometric analysis of the frequency and number of CD34 + CD45 + cells on day 10 generated in VTN or MTG‐coated culture. n = 6. I, Representative flow cytometric analysis of the CD43 expression in the day 6 cells coated with different concentrations of VTN or MTG. n = 3. J, The cell number of CD43 + cells generated in different concentrations of VTN on day 6. 1 μg/mL was set as a control and normalized to 1. n = 3. Experiments were performed on H1 unless otherwise indicated

    Journal: Cell Proliferation

    Article Title: Vitronectin‐activated αvβ3 and αvβ5 integrin signalling specifies haematopoietic fate in human pluripotent stem cells, et al. Vitronectin‐activated αvβ3 and αvβ5 integrin signalling specifies haematopoietic fate in human pluripotent stem cells

    doi: 10.1111/cpr.13012

    Figure Lengend Snippet: VTN promotes early haematopoietic differentiation of hPSCs, compared to MTG. A, Schematic showing the strategy for the generation of hPSC‐derived haematopoietic cells in VTN or MTG‐coated cultures. B and C, Flow cytometric analysis of the frequency and number of CD43 + and CD34 + CD43 ‐ cells on day 6. n = 3. D, The representative images showed that haematopoietic‐like cells with round shape and endothelium‐like cells undergoing EHT emerged in VTN‐coated culture on day 6. Scale bars, left 100 µm, right 50 µm. n = 3. E, qRT‐PCR analysis of RUNX1 , GATA2 and MYB expression in the day 6 cells coated with VTN or MTG. n = 3. F, CD43 + cell number on day 8 generated in VTN, MTG or GR‐MTG‐coated culture. MTG was set as a control and normalized to 1. n = 3. G and H, Flow cytometric analysis of the frequency and number of CD34 + CD45 + cells on day 10 generated in VTN or MTG‐coated culture. n = 6. I, Representative flow cytometric analysis of the CD43 expression in the day 6 cells coated with different concentrations of VTN or MTG. n = 3. J, The cell number of CD43 + cells generated in different concentrations of VTN on day 6. 1 μg/mL was set as a control and normalized to 1. n = 3. Experiments were performed on H1 unless otherwise indicated

    Article Snippet: The dissociated cells were resuspended in FACS buffer and labelled with fluorochrome‐conjugated anti‐human CD34‐APC/Cyanine7 (clone 561, BioLegend), KDR‐PE (clone ES8‐20E6, Miltenyi Biotec), CD31‐FITC (clone AC128, Miltenyi Biotec), CD144‐APC (clone 16B1, eBioscience), CD43‐PerCP (clone TP1/36, Abcam), CD45‐APC (clone 2D1, BioLegend), CD144‐PE (clone BV9, BioLegend), CD43‐FITC (clone MEM‐59, BioLegend), CD73‐PE/Cyanine7 (clone AD2, BioLegend), CD184‐APC (clone 12G5, BioLegend), CD51/61‐FITC (clone 23C6, BioLegend), integrin β5‐PE (clone AST‐3T, BioLegend) and APLNR‐Alexa Fluor 647 (clone 72133R, RD system).

    Techniques: Derivative Assay, Quantitative RT-PCR, Expressing, Generated

    VTN specifies haematopoietic‐fated mesoderm and enhances HE generation from the mesoderm. A, qRT‐PCR analysis of MIXL1 , T and TBX6 expression in the day 2 VTN or MTG‐coated cells. n = 3. B and C, Flow cytometric analysis of the frequency of T‐GFP + and APLNR + cells in the day 2 cells coated with VTN or MTG. n = 3. D and E, Flow cytometric analysis of the frequency and number of CD34 + CD144 + cells in the day 4 VTN or MTG‐coated cells. n = 3. F, qRT‐PCR analysis of RUNX1 and GATA2 expression in the day 4 cells coated with VTN or MTG. n = 3. G, Scheme depicting the strategy used for evaluating the role of VTN in the fate determination of mesoderm cells and their development into HE cells. The day 2 T‐GFP + mesodermal cells coated with VTN or MTG were sorted and re‐seeded on VTN and MTG, respectively, for an additional 2 days of HE induction. H, The fold change of CD34 + CD144 + cell number generated in the day 2 T‐GFP + mesodermal cells coated with VTN or MTG following an additional two‐day culture in VTN or MTG. M‐M was set as a control and normalized to 1. n = 3. Experiments were performed on H1 unless otherwise indicated

    Journal: Cell Proliferation

    Article Title: Vitronectin‐activated αvβ3 and αvβ5 integrin signalling specifies haematopoietic fate in human pluripotent stem cells, et al. Vitronectin‐activated αvβ3 and αvβ5 integrin signalling specifies haematopoietic fate in human pluripotent stem cells

    doi: 10.1111/cpr.13012

    Figure Lengend Snippet: VTN specifies haematopoietic‐fated mesoderm and enhances HE generation from the mesoderm. A, qRT‐PCR analysis of MIXL1 , T and TBX6 expression in the day 2 VTN or MTG‐coated cells. n = 3. B and C, Flow cytometric analysis of the frequency of T‐GFP + and APLNR + cells in the day 2 cells coated with VTN or MTG. n = 3. D and E, Flow cytometric analysis of the frequency and number of CD34 + CD144 + cells in the day 4 VTN or MTG‐coated cells. n = 3. F, qRT‐PCR analysis of RUNX1 and GATA2 expression in the day 4 cells coated with VTN or MTG. n = 3. G, Scheme depicting the strategy used for evaluating the role of VTN in the fate determination of mesoderm cells and their development into HE cells. The day 2 T‐GFP + mesodermal cells coated with VTN or MTG were sorted and re‐seeded on VTN and MTG, respectively, for an additional 2 days of HE induction. H, The fold change of CD34 + CD144 + cell number generated in the day 2 T‐GFP + mesodermal cells coated with VTN or MTG following an additional two‐day culture in VTN or MTG. M‐M was set as a control and normalized to 1. n = 3. Experiments were performed on H1 unless otherwise indicated

    Article Snippet: The dissociated cells were resuspended in FACS buffer and labelled with fluorochrome‐conjugated anti‐human CD34‐APC/Cyanine7 (clone 561, BioLegend), KDR‐PE (clone ES8‐20E6, Miltenyi Biotec), CD31‐FITC (clone AC128, Miltenyi Biotec), CD144‐APC (clone 16B1, eBioscience), CD43‐PerCP (clone TP1/36, Abcam), CD45‐APC (clone 2D1, BioLegend), CD144‐PE (clone BV9, BioLegend), CD43‐FITC (clone MEM‐59, BioLegend), CD73‐PE/Cyanine7 (clone AD2, BioLegend), CD184‐APC (clone 12G5, BioLegend), CD51/61‐FITC (clone 23C6, BioLegend), integrin β5‐PE (clone AST‐3T, BioLegend) and APLNR‐Alexa Fluor 647 (clone 72133R, RD system).

    Techniques: Quantitative RT-PCR, Expressing, Generated

    Myeloma Cells Are Sensitive to VV (A) Infectivity of leukemia/myeloma cell lines to VV. Cell lines derived from acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), malignant lymphoma, and multiple myeloma were infected with a firefly-luciferase-expressing VV (LC16m8Δ-B5R-FlucIRESgfp) at an MOI of 1. Luciferase activity was determined at 12 hr after infection. Data represent the means and SD of three independent experiments. (B) Cell viability after infection. Cells (1 × 10 4 /well) were seeded in 96-well plates and cultured for 72 hr in the absence or presence of different concentrations of the VV strain LC16m8Δ-B5R-FlucIRESgfp (MOIs = 0–8). The number of viable cells was determined using the Cell Counting Kit-8 (Dojindo). Data represent the mean and SD of three independent experiments. (C) Cells were infected with LC16m8Δ-B5Rgfp at an MOI of 0.1. Extracellular enveloped virus (EEV) and intracellular mature virus (IMV) were collected from supernatant and cell pellet at 72 hr after infection. Harvested virus was titrated by the infection to RK13 cells. Data represent the means and SD of three independent experiments. (D) Infectivity of myeloma patient bone marrow cells. Bone marrow mononuclear cells derived from a myeloma patient were infected with LC16m8Δ-B5Rgfp at an MOI of 1 and cultured for 48 hr. The frequency of virus-infected cells (GFP + ) was compared among CD34 + cells (hematopoietic progenitors), CD138 + cells (myeloma), CD3 + cells (T lymphocytes), CD19 + cells (B lymphocytes), and CD14 + cells (monocytes). Histograms of non-infected cells (blue) are overlaid with infected cells (red).

    Journal: Molecular Therapy Oncolytics

    Article Title: Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma

    doi: 10.1016/j.omto.2017.07.001

    Figure Lengend Snippet: Myeloma Cells Are Sensitive to VV (A) Infectivity of leukemia/myeloma cell lines to VV. Cell lines derived from acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), malignant lymphoma, and multiple myeloma were infected with a firefly-luciferase-expressing VV (LC16m8Δ-B5R-FlucIRESgfp) at an MOI of 1. Luciferase activity was determined at 12 hr after infection. Data represent the means and SD of three independent experiments. (B) Cell viability after infection. Cells (1 × 10 4 /well) were seeded in 96-well plates and cultured for 72 hr in the absence or presence of different concentrations of the VV strain LC16m8Δ-B5R-FlucIRESgfp (MOIs = 0–8). The number of viable cells was determined using the Cell Counting Kit-8 (Dojindo). Data represent the mean and SD of three independent experiments. (C) Cells were infected with LC16m8Δ-B5Rgfp at an MOI of 0.1. Extracellular enveloped virus (EEV) and intracellular mature virus (IMV) were collected from supernatant and cell pellet at 72 hr after infection. Harvested virus was titrated by the infection to RK13 cells. Data represent the means and SD of three independent experiments. (D) Infectivity of myeloma patient bone marrow cells. Bone marrow mononuclear cells derived from a myeloma patient were infected with LC16m8Δ-B5Rgfp at an MOI of 1 and cultured for 48 hr. The frequency of virus-infected cells (GFP + ) was compared among CD34 + cells (hematopoietic progenitors), CD138 + cells (myeloma), CD3 + cells (T lymphocytes), CD19 + cells (B lymphocytes), and CD14 + cells (monocytes). Histograms of non-infected cells (blue) are overlaid with infected cells (red).

    Article Snippet: Flow Cytometry Allophycocyanin (APC)-labeled antibodies against human CD3, CD14, CD19, CD34, and CD138 were purchased from BioLegend.

    Techniques: Infection, Derivative Assay, Luciferase, Expressing, Activity Assay, Cell Culture, Cell Counting

    Evidence of humanization in mHM cohorts. (a) Comparison of the average percentage of human CD45+ immune cells within the bone marrow of cohorts engrafted with HSPCs only (first six cohorts on the left, shaded in gray) and those engrafted with an HSPC- MSC mixture, along with the number of mice in each cohort. (b) Chart comparing the average CD45+ cell percentage (light green) and the average CD34-45+ HSPCs percentage (dark green) in mouse cohorts generated using only HSPCs and those created from HSPC-MSCs. *P=0.007. (c) Comparison of the percentage of human T cells, B cells, and monocytes found in the blood of mice engrafted with HSPCs and HSPC-MSCs. *P=

    Journal: Molecular carcinogenesis

    Article Title: Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer

    doi: 10.1002/mc.22887

    Figure Lengend Snippet: Evidence of humanization in mHM cohorts. (a) Comparison of the average percentage of human CD45+ immune cells within the bone marrow of cohorts engrafted with HSPCs only (first six cohorts on the left, shaded in gray) and those engrafted with an HSPC- MSC mixture, along with the number of mice in each cohort. (b) Chart comparing the average CD45+ cell percentage (light green) and the average CD34-45+ HSPCs percentage (dark green) in mouse cohorts generated using only HSPCs and those created from HSPC-MSCs. *P=0.007. (c) Comparison of the percentage of human T cells, B cells, and monocytes found in the blood of mice engrafted with HSPCs and HSPC-MSCs. *P=

    Article Snippet: The initial HSPC population was calculated by flow cytometry, using human CD34 and CD45 (Biolegend, San Diego, CA; Cat#343608, 368510) antibodies.

    Techniques: Mouse Assay, Generated

    The proportions of TNF-α–producing CD14 + monocytes arelower than in the controls in FA and DBA. Bone marrow mononuclear cells werestimulated with 1 μg/ml of LPS for 4 h and stained for CD19 and CD14, andthen for intracellular

    Journal: British journal of haematology

    Article Title: Cytokine production by bone marrow mononuclear cells in inherited bone marrow failure syndromes

    doi: 10.1111/bjh.12475

    Figure Lengend Snippet: The proportions of TNF-α–producing CD14 + monocytes arelower than in the controls in FA and DBA. Bone marrow mononuclear cells werestimulated with 1 μg/ml of LPS for 4 h and stained for CD19 and CD14, andthen for intracellular

    Article Snippet: Reagent resources were as follows: Phorbol 12-myristate 13-acetate (PMA),ionomycin, LPS: Sigma-Aldrich; Fluorescein isothiocyanate (FITC)-conjugatedanti-CD45 and phycoerythrin (PE)-conjugated anti-CD14 Simultest: BD Biosciences(San Jose, CA, USA); Brefeldin A solution (1000×), 10×permeabilization solution, antibodies to CD19 (PE-cyanin 7 [PC7]) andIFN-γ (Alexa Fluor 488 [AF488]): eBioscience (San Diego, CA, USA);Allophycocyanin (APC)-conjugated anti-CD34 and -CD14, PE-conjugatedanti-TNF-α and -TLR4 antibodies: BioLegend (San Diego, CA, USA); andPhycoerythrin-Texas Red (ECD)-conjugated CD3: Beckman Coulter (Brea, CA,USA).

    Techniques: Staining

    CD14 + monocytes from the majority of IBMFS patients are hypersensitiveto low-dose LPS. Bone marrow mononuclear cells were stimulated with 1.0, 0.1, or0.001 μg/ML of LPS for 4 h and stained for CD14, then for intracellularTNF-α. All

    Journal: British journal of haematology

    Article Title: Cytokine production by bone marrow mononuclear cells in inherited bone marrow failure syndromes

    doi: 10.1111/bjh.12475

    Figure Lengend Snippet: CD14 + monocytes from the majority of IBMFS patients are hypersensitiveto low-dose LPS. Bone marrow mononuclear cells were stimulated with 1.0, 0.1, or0.001 μg/ML of LPS for 4 h and stained for CD14, then for intracellularTNF-α. All

    Article Snippet: Reagent resources were as follows: Phorbol 12-myristate 13-acetate (PMA),ionomycin, LPS: Sigma-Aldrich; Fluorescein isothiocyanate (FITC)-conjugatedanti-CD45 and phycoerythrin (PE)-conjugated anti-CD14 Simultest: BD Biosciences(San Jose, CA, USA); Brefeldin A solution (1000×), 10×permeabilization solution, antibodies to CD19 (PE-cyanin 7 [PC7]) andIFN-γ (Alexa Fluor 488 [AF488]): eBioscience (San Diego, CA, USA);Allophycocyanin (APC)-conjugated anti-CD34 and -CD14, PE-conjugatedanti-TNF-α and -TLR4 antibodies: BioLegend (San Diego, CA, USA); andPhycoerythrin-Texas Red (ECD)-conjugated CD3: Beckman Coulter (Brea, CA,USA).

    Techniques: Staining